宫颈癌能否减量治疗:基于肿瘤反应的低危患者筛选研究
该多中心回顾性研究基于469例宫颈癌患者,识别出鳞癌、肿瘤缩小率≥29%、近距离放疗前肿瘤≤4cm、总治疗时间<9周四个低危因素。162例(34.5%)符合低危标准,各CTVHR D90剂量组4年局部控制率均超过90%,且直肠和膀胱D2cc及晚期不良事件随剂量降低而减少。低危患者接受CTVHR D90<80Gy即可获得良好局部控制。
要点
- 低危因素:鳞癌、肿瘤缩小率≥29%、近距离放疗前肿瘤≤4cm、总治疗时间<9周。
- 低危患者各CTVHR D90剂量组4年局部控制率均超过90%。
- CTVHR D90降低时直肠和膀胱D2cc及晚期不良事件发生率下降。
核心结论
- 低危宫颈癌患者接受CTVHR D90<80Gy即可获得良好局部控制。
- 基于肿瘤反应的个体化减量治疗策略可用于宫颈癌。
研究设计与样本
- 亚洲国际多中心回顾性研究,纳入日本13家、泰国1家、韩国1家机构共469例患者。
主要发现
- 469例中162例(34.5%)符合低危标准。
- 低危组按CTVHR D90分为50-60Gy(63例)、60-70Gy(41例)、70-80Gy(43例)和>80Gy(15例)。
- 各剂量组4年无进展生存率范围为66%至80%,4年局部控制率均超过90%。
- 直肠和膀胱D2cc及晚期不良事件发生率随CTVHR D90降低而减少。
关键数值与推荐
- 低危因素包括:鳞状细胞癌、肿瘤缩小率≥29%、近距离放疗前肿瘤大小≤4cm、总治疗时间<9周。
临床怎么用
- 对符合低危因素的患者可考虑降低CTVHR D90至<80Gy以减少晚期不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The majority of uterine cervical cancer is known to be related to human papillomavirus (HPV), and HPV-related tumors are known to be radio-sensitive. In the management of HPV-related oropharyngeal cancer, de-intensification of treatment has been attempted; however, no such attempt is performed in the management of cervical cancer. The aim of this study was to identify a group of patients who can safely be treated by de-escalated treatment intensity. METHODS: From the Asian international multi-institutional retrospective study involving 13 Japanese, one Thailand, and one Korean institutions based on 469 patients, squamous cell carcinoma (Scc), tumor reduction ratio ≥29%, tumor size before brachytherapy ≤4 cm, and total treatment time (TTT) <9 weeks were identified as factors having an influence on local control. Based on these findings, low-risk patients having these four factors were extracted, and treatment outcomes categorized in 10 Gy increment of CTVHR D90 were compared. RESULTS: Among 469 patients, 162 patients (34.5%) met the criteria of low-risk group, and 63, 41, 43, and 15 patients were categorized in CTVHR D90 50-60 Gy, 60-70 Gy, 70-80 Gy, and >80 Gy, respectively. While 4-y progression-free survival ranged from 66 to 80%, 4-y local control was consistently over 90% in every dose group. Rectum and bladder D2cc and incidence of late adverse events decreased as CTVHR D90 decreased. CONCLUSIONS: The low-risk patients achieved favorable local control with CTVHR D90 <80 Gy. A personalized treatment strategy based on tumor response could also be adopted for cervical cancer.
引用
- Murakami N, Ando K, Murata M, et al. Why not de-intensification for uterine cervical cancer? Gynecol Oncol. 2021. PMID: 34294413. doi:10.1016/j.ygyno.2021.07.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。